Comparison · NCT04625725-1e59c014
AZD7442 vs Placebo: The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AZD7442 vs Placebo: The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP. Trial comparisons, record NCT04625725-1e59c014. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04625725-1e59c014
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.000581 | 0.000159 | 0.00212 | wilson | |
| Risk in group 2 | 0.00635 | 0.00355 | 0.0113 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00577 | -0.0108 | -0.00258 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.0915 | 0.0203 | 0.412 | log | |
| Odds ratio, group 1 over group 2 | 0.0909 | 0.0201 | 0.411 | log | |
| Number needed to treat, for one fewer participant with the outcome on AZD7442 than on Placebo | 173 | 92.8 | 388 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AZD7442 | 300 mg (AZD8895 and AZD1061) | 2 | 3,441 | OG000 |
| Group 2 | Placebo | Saline placebo | 11 | 1,731 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP
- Description
- To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of severe or critical symptomatic COVID-19
- Time frame
- 366 Days
- Population
- All randomized and dosed participants who did not have a prior SARS-CoV-2 RT-PCR-positive confirmed COVID-19 infection
Source ClinicalTrials.gov
Trial
- Title
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
- NCT number
- NCT04625725
- Phases
- PHASE3
- Conditions
- COVID-19
- Interventions
- AZD7442, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2022-12-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04625725?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04625725-1e59c014